Embed Size (px)
Citation preview
Name __________________________________Address ________________________________City ____________________________________State/ZIP _______________________________Home Phone (_______) _____________________E-mail Address ____________________________Select: RPh RN Pharm Tech
Other ____________________________
Indicate sessions/options for which you are registering:Saturday a.m. - Public Health Poster Presentations ..... free
if poster CEU credit requested ............................$10
Lunch ........................................................................ $15 Special meal consideration ________________
Saturday p.m. - CE Lecture Session ....................... $45
Total $ __________
If you must cancel, a $20 processing fee will be assessed per person for
cancellations received prior to the start of the program. We are unable to
refund after the program is underway. NDSU Distance & Continuing Education
reserves the right to cancel any program and in such case, a full refund is made.
* NOTE: If you do not pre-register the cost for the Sat p.m. session will be $70 (not including lunch)
Call (701) 231-5376 for further information
Individuals with disabilities are invited to request reasonable accommodations
to participate in NDSU-sponsored programs and events. To request an
accommodation, please contact Lisa McNamara at [email protected].
MID-WINTER PHARMACY SEMINAR 2012
Pre-Registration, Fees and Continuing Education Units (CEUs)
We strongly encourage participants to pre-register for the Mid-Winter Pharmacy Seminar. Registration will take place before the start of the session on Saturday. If you have pre-registered and are unable to attend, you must contact DCE before the start of the program for your fees to be refunded.
Call (701) 231-5376 for more information.
ProgramLocated in Memorial Union, Upper Level–NDSU
8:15am Breakfast sponsored by
8:30-9:00am RegistrationWanda Roden, RPh and Rebecca Focken, PharmD will be available in the morning to answer questions related to IPPE and APPE and provide experiential education information
9:00-Noon Public Health Poster Presentations
Noon-12:30pm Lunch
12:30-1:30pm Preventing Cardiovascular Disease in Women by Anne Ottney, PharmD
1:30-3:30pm Therapeutic Update in Cardiovascular Disease by Richard Clarens, PharmD
Free parking on Saturday in lots E (visitor lot), C, & AD
Conference is in Memorial Union, upper level
North Dakota State University does not discriminate on the basis of age, color, disability, gender expression/identity, genetic information, marital status, national origin, public assistance status, sex, sexual orientation, status as a U.S. veteran, race or religion. Direct inquiries to the Vice President for Equity, Diversity and Global Outreach, 205 Old Main, (701)231-7708.
Please register on or before February 1, 2012
• Online at http://ndsu.me/dce12mwpharm or• Mail this completed form with check (payable to NDSU) to:
Distance & Continuing Education - NDSUNoncredit ProgramsP.O. Box 6050 Dept 2020Fargo, ND 58108
MID-WINTERPHARMACY SEMINAR+ NDSU Pharmacy Student Poster Presentations
2012
February 4th, 2012NDSU Memorial UnionFargo, North Dakota
Objectives:After completing each portion of the program, the participant should be able to:
Morning – Public Health Poster Presentations
• Discuss public health topics and identify interventions that can be made to improve healthcare within a variety of patient populations.
• Earn up to 3 credits, 1 hour for every 5 posters evaluated.
Afternoon (Earn 3 credits)Preventing Cardiovascular Disease in Women Anne Ottney, PharmD• Recognize gender-based differences in the
cardiovascular system.• Review non-drug strategies for preventing
cardiovascular disease (CVD) in women.• Discuss the role of aspirin in preventing
myocardial infarction and stroke in women.• Identify potentially inappropriate
medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
Target Audience:This program is intended for community, hospital, and consultant pharmacists. It is also appropriate for pharmacy technicians, physicians, mid-level practitioners, and nurses with an interest in the subject area.
Certifi cate of Attendance:A statement of credit will be mailed to those participating in these programs within 6 weeks. Attendance at the sessions and completion of an evaluation form will be required to receive continuing education credit. The College of Pharmacy, Nursing, and Allied Sciences is awarding Continuing Pharmacy Education credit for the programs as follows:
Poster Presentation – 1 hour for every 5 posters evaluated.ACPE # 0047-0000-12-007-L01-P
Lecture Seminar – 3 hoursACPE # 0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
management of atrial fi brillation including rate control, rhythm control and anticoagulation.management of atrial fi brillation including rate control, rhythm control and anticoagulation.management of atrial fi brillation including rate control, rhythm control and anticoagulation.management of atrial fi brillation including rate control, rhythm control and anticoagulation.management of atrial fi brillation including rate control, rhythm control and anticoagulation.management of atrial fi brillation including rate control, rhythm control and anticoagulation.
for secondary prevention of coronary heart
management of atrial fi brillation including rate control, rhythm control and anticoagulation.
recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
management of atrial fi brillation including rate control, rhythm control and anticoagulation.
recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
niacin ( LDL-C. non-HDL-C, HDL-C and TG).
recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
niacin ( LDL-C. non-HDL-C, HDL-C and TG).
recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.control, rhythm control and anticoagulation.
of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.control, rhythm control and anticoagulation.
of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate management of atrial fi brillation including rate control, rhythm control and anticoagulation.
of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate management of atrial fi brillation including rate control, rhythm control and anticoagulation.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the • Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
therapy options according to the JNC7 and
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart for secondary prevention of coronary heart
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart for secondary prevention of coronary heart disease events.
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, • After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, • After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the management of atrial fi brillation including rate control, rhythm control and anticoagulation.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the management of atrial fi brillation including rate
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the management of atrial fi brillation including rate
medications for preventing CVD in women.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues • Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the
medications for preventing CVD in women.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues • Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the
medications for preventing CVD in women.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and recent citations in the literature.recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart disease events.
• Explain the current approach to the
myocardial infarction and stroke in women.
medications for preventing CVD in women.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and recent citations in the literature.recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
myocardial infarction and stroke in women.
medications for preventing CVD in women.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy for secondary prevention of coronary heart
myocardial infarction and stroke in women.
medications for preventing CVD in women.
Therapeutic Update in Cardiovascular Disease
• Compare and contrast BP goals and fi rst-line • Compare and contrast BP goals and fi rst-line therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line • Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines, recommend risk-factor modifi cation therapy
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmDRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines,
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmDRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• After reviewing current guidelines,
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseTherapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and niacin ( LDL-C. non-HDL-C, HDL-C and TG).
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues of dyslipidemias with statins, fi brates and
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
• Discuss the current management issues
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate • Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and recent citations in the literature.
identify at least three objectives from each poster.
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and
identify at least three objectives from each poster.
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing myocardial infarction and stroke in women.myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
therapy options according to the JNC7 and
identify at least three objectives from each poster.
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
identify at least three objectives from each poster.
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD• Compare and contrast BP goals and fi rst-line
identify at least three objectives from each poster.
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD
continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular DiseaseRichard Clarens, PharmD
continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular Disease
presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
Therapeutic Update in Cardiovascular Disease
presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate medications for preventing CVD in women.
receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate
students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate
students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing myocardial infarction and stroke in women.
• Identify potentially inappropriate
students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing
students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing • Discuss the role of aspirin in preventing
poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
• Discuss the role of aspirin in preventing
poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing cardiovascular disease (CVD) in women.
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
• Review non-drug strategies for preventing
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of lectures and case studies.
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
The Saturday afternoon session will consist of
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
0047-0000-12-006-L01-P
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
0047-0000-12-006-L01-P
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and identify at least three objectives from each poster.
0047-0000-12-006-L01-P
The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and
0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively engage in discussion with the students, and
0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively
0047-0000-12-007-L01-P
0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving continuing education units (CEUs) must actively
0047-0000-12-007-L01-P
0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour of continuing education credit. Those receiving
0047-0000-12-007-L01-P
– 3 hours0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour
0047-0000-12-007-L01-P
– 3 hours0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster presentations, by reviewing fi ve posters for 1 hour
0047-0000-12-007-L01-P
– 3 hours0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster
0047-0000-12-007-L01-P
– 3 hours0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will receive continuing education credit for the poster
0047-0000-12-007-L01-P
– 3 hours0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy students on public health issues. Pharmacists will
0047-0000-12-007-L01-P
Lecture Seminar – 3 hours0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy
0047-0000-12-007-L01-P
Lecture Seminar0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of poster presentations by NDSU P3 pharmacy
0047-0000-12-007-L01-P
Lecture Seminar0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of
0047-0000-12-007-L01-P
Lecture SeminarACPE # 0047-0000-12-006-L01-P
Program Goals:The Saturday morning session will consist of
0047-0000-12-007-L01-P
Lecture SeminarACPE #
Program Goals:
0047-0000-12-007-L01-P
Lecture SeminarACPE #
Program Goals:
0047-0000-12-007-L01-P
Lecture SeminarACPE #
0047-0000-12-007-L01-P
Lecture SeminarACPE #
ACPE # 0047-0000-12-007-L01-P
Lecture SeminarACPE #
evaluated.ACPE #
Lecture Seminar
evaluated.ACPE #
Lecture Seminar
evaluated.ACPE # evaluated.ACPE # evaluated.ACPE # evaluated.evaluated.
http://ndsu.me/dce12mwpharm
Non
-Pro
fi t O
rg.
U.S
. Pos
tage
PAID
Perm
it N
o. 8
18Fa
rgo,
N. D
ak.
CO
NTA
CT
DC
E:
Dis
tanc
e &
Co
ntin
uing
Ed
ucat
ion
1919
N. U
nive
rsit
y D
rive
Dep
t. 2
020
PO
Box
60
50Fa
rgo,
ND
581
08-
60
50
Toll
free
: 1-
80
0-7
26-1
724
P
hone
: 70
1-23
1-70
15F
ax:
701-
231-
7016
Onl
ine:
w
ww
.nd
su.e
du/
dce
Register online at http://ndsu.me/dce12mwpharm
